CR11442A - Producto de dispersion solida de drogas basadas en n-aril urea - Google Patents

Producto de dispersion solida de drogas basadas en n-aril urea

Info

Publication number
CR11442A
CR11442A CR11442A CR11442A CR11442A CR 11442 A CR11442 A CR 11442A CR 11442 A CR11442 A CR 11442A CR 11442 A CR11442 A CR 11442A CR 11442 A CR11442 A CR 11442A
Authority
CR
Costa Rica
Prior art keywords
solid dispersion
urea
aril
dispersion product
drugs based
Prior art date
Application number
CR11442A
Other languages
English (en)
Spanish (es)
Inventor
Schroeder Rudolf
Heitermann Tanja
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of CR11442A publication Critical patent/CR11442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR11442A 2007-10-19 2010-05-19 Producto de dispersion solida de drogas basadas en n-aril urea CR11442A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CR11442A true CR11442A (es) 2010-09-06

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11442A CR11442A (es) 2007-10-19 2010-05-19 Producto de dispersion solida de drogas basadas en n-aril urea

Country Status (18)

Country Link
EP (1) EP2197425A2 (pt)
JP (1) JP2011500649A (pt)
KR (1) KR20100087170A (pt)
CN (1) CN101827584A (pt)
AU (1) AU2008313622A1 (pt)
BR (1) BRPI0818340A2 (pt)
CA (1) CA2699301A1 (pt)
CO (1) CO6270206A2 (pt)
CR (1) CR11442A (pt)
DO (1) DOP2010000117A (pt)
EC (1) ECSP10010183A (pt)
GT (1) GT201000102A (pt)
MX (1) MX2010004291A (pt)
PA (1) PA8800101A1 (pt)
RU (1) RU2010119929A (pt)
UA (1) UA100865C2 (pt)
WO (1) WO2009050291A2 (pt)
ZA (1) ZA201002095B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CA2856406C (en) * 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
ECSP10010183A (es) 2010-06-29
BRPI0818340A2 (pt) 2015-04-22
RU2010119929A (ru) 2011-11-27
UA100865C2 (ru) 2013-02-11
AU2008313622A1 (en) 2009-04-23
MX2010004291A (es) 2010-08-02
WO2009050291A2 (en) 2009-04-23
DOP2010000117A (es) 2010-05-15
CN101827584A (zh) 2010-09-08
ZA201002095B (en) 2011-11-30
JP2011500649A (ja) 2011-01-06
CA2699301A1 (en) 2009-04-23
WO2009050291A3 (en) 2010-04-08
CO6270206A2 (es) 2011-04-20
EP2197425A2 (en) 2010-06-23
GT201000102A (es) 2012-03-12
KR20100087170A (ko) 2010-08-03
PA8800101A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
DOP2010000117A (es) Producto de dispersion solida de drogas basadas en n-aril urea
AR080736A1 (es) Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CR9292A (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
AR062059A1 (es) Espuma farmaceutica con acido graso
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CO6251200A2 (es) Metodo para modular la tasa de liberacion de ingredientes activos microencapsulados usado paa la proteccion de cultivos
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
WO2010041141A3 (en) Oil-based foamable carriers and formulations
NZ602442A (en) A fast dissolving pharmaceutical composition
UY32761A (es) Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
CO7131367A2 (es) Formulación compuesta que comprende una tableta esferoidal de múltiples unidades (must) en cápsulada en cápsula dura y método para su preparación
CL2013003161A1 (es) Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion.
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
CO2021016449A2 (es) Composiciones terapéuticas estables en solventes polares aproticos y métodos de fabricación de las mismas
ECSP15022501A (es) Dispersión sólida de un modulador selectivo de los receptores de progesterona
CL2007001981A1 (es) Composicion que comprende al menos un principio activo agroquimico del grupo de los piretroides, al menos un tensioactivo, y al menos un disolvente no miscible en agua; procedimiento para la lucha contra las plagas animales; y su uso.
CL2008000931A1 (es) Particula solidad de vacuna oral entrecruzada que contiene un ingrediente farmaceuticamente activo un bioadhesivo, un oligasacarido, una mezcla mediadiora que comprende un emulsionante y uno o mas monosacaridos y/o disacaridos; metodo para su preparacion; uso de la particula solidad de vacuna oral.
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
CO6270249A2 (es) Fibra, pelicula o espuma que comprende un plastificador y un gel ligado a arcilla cargado y metodos para su produccion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)